Stocks● Neutral
Apollo Hospitals Plans 1,500 New Beds After 36% Profit Jump
Apollo Hospitals Q4 profit jumps 36% to ₹529 crore as CEO cites clinical differentiation. The 1,500-bed pipeline and diagnostics-pharmacy flywheel drive the margin story.
Continue with
Apollo Hospitals Enterprise Ltd (AHEL) posted a 36% year-on-year rise in consolidated net profit to ₹529 crore for the quarter ended March, while outlining an aggressive capacity expansion plan. The company will add 1,500 beds over the next 12–18 months through a combination of new hospitals and adjacent expansions in existing facilities.
CEO Dr Madhu Sasidhar framed the growth as a multi-year outcome of clinical programme differentiation, not a one-time demand spike. “We think capacity is a strategically important lever… it will place us as the largest player substantially in terms of bed capacity. Beyond that, if you look at the growth that we've seen reported, that is not a one-time growth or demand generation,” he said.
Q4 Net Profit Jumps 36% as Margins Expand 154 bps
Revenue for the quarter grew 18% year-on-year to ₹6,605 crore from ₹5,592 crore. Operating EBITDA came in at ₹1,011 crore, up 31.5% from ₹769 crore. EBITDA margins expanded by 154 basis points to 15.3%, reflecting operating leverage from the existing network and early contributions from new beds.
For the full fiscal year FY26, the hospitals business reported revenue of ₹12,555 crore, up 13% from the previous year. The diagnostics and retail health business grew 20% to ₹1,865 crore. The omnichannel pharmacy arm, Apollo HealthCo, posted a 19% revenue increase to ₹10,808 crore. Overall group revenue grew 16% to ₹25,229 crore.
The margin improvement is the key earnings takeaway. New hospitals typically operate at sub-10% EBITDA margins for the first 12–18 months. Apollo’s ability to expand margins while commissioning new capacity suggests the legacy network is still generating strong incremental returns.
1,500-Bed Pipeline: Where the Beds Are Going
Apollo currently operates 10,970 beds across 78 hospitals. The company commissioned four new hospitals in FY26 – in Pune, Kolkata, Hyderabad, and Delhi. Of those, 670 beds are expected to be operationalized in the next 12–18 months. CFO Krishnan Akhileswaran confirmed the timeline to Mint.
- Sarjapur (near Bengaluru): A new 170-bed hospital will open in Q1FY27.
- Gurugram: A 400-bed facility is scheduled for Q2FY27.
- Hyderabad and Bengaluru: Adjacent expansion opportunities in existing hospitals, where management expects faster EBITDA flow-through because the infrastructure and patient referral channels are already in place.
The revenue contribution from new beds was just 2% in Q4. The company expects that share to accelerate this year as these hospitals ramp up occupancy.
“When we expand adjacent, we get the ability to see that revenue flow through to EBITDA much more rapidly,” Sasidhar said. This approach minimizes the usual drag from greenfield facilities and supports the margin story.
Clinical Programmes as the Moat Over Capacity Additions
Management emphasized that bed count alone is not a durable advantage. What drives occupancy and pricing power are the clinical programmes – from oncology to high-end diagnostics and molecular genetics. Apollo has been investing in assembling specialist teams and the required infrastructure over several years.
This focus creates a barrier that pure capacity expansions by competitors find harder to replicate. A new bed is a commodity. A referral network built around a renowned oncology or cardiac programme is not.